Nikan Pharmaceuticals

Developing the first-ever antiviral drug for treatment of human papillomavirus (HPV). Our compound is oral with anticipated twice a day dosing. Our initial therapeutic focus is recurrent respiratory papillomatosis (RRP), a serious potentially lethal orphan disease in children.